Table 5 Ongoing MET inhibitor clinical trials [61]
From: Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer
ClinicalTrials.gov identifier | Study agent | Trial description |
|---|---|---|
NCT02609776 | Amivantamab | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and c-MET Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer |
NCT03175224 | APL-101 | Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With cMETex14 Skip Mutations and cMET Dysregulation Advanced Solid Tumors |
NCT01639508 | Cabozantinib | A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes ROS1 or NTRK Fusions or Increased Met or AXL Activity |
NCT02414139 | Capmatinib | A Phase II, Multicenter Study of Oral c-MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC)(Geometry Mono-1) |
NCT04270591 | Glumetinib | A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Glumetinib (SCC244), a Selective MET Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer Harboring MET alterations |
NCT03539536 | Telisotuzumab vedotin | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met + Non-Small Cell Lung Cancer |
NCT02864992 | Tepotinib | A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-Small Cell Lung Cancer with METex14 (METex14) Skipping Alterations or MET Amplification (VISION) |
NCT03993873 | TPX-0022 | Phase 1 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET |
NCT04077099 | REGN5093 | A Phase 1/2 Study of REGN5093 in Patients with MET-Altered Advanced Non-Small Cell Lung Cancer |
NCT04323436 | Capmatinib | A Double-blind, Placebo-Controlled, Randomized, Phase II Study Evaluating the Efficacy and Safety of Capmatinib and Spartalizumab vs Capmatinib and Placebo as 1st Line Treatment for Advanced NSCLC Patients With METex14 Skipping Mutation |